ACE Pharma SRL
0.6 FTEThe score of ACE Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -3 % Total assets -10 % Headcount (avg FTE) +200 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ACE Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Jul 2026
- Year ended 31 Dec 2024filed on 03 Jul 2025
- Year ended 31 Dec 2023filed on 20 Mar 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 24 Jun 2022
ACE Pharma's financial analysis
- Solvency76.6%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ACE Pharma
ACE Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0436.322.331
- VAT number
- BE0436322331
- Peppol
- Registered · 0208:0436322331 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Jan 1989
- Registered office
- 4347 Fexhe-le-Haut-Clocher
- Size
- Micro · 0.6 FTE
- Latest accounts
- 2025 · filed on 06 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
ACE Pharma (SRL) has been based in Fexhe-le-Haut-Clocher since 1989, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 1,837 € and equity of 221,792 €; its revenue is not published. With 0.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 76.6%, above the median of its sector (41.5%).
Companies similar to ACE Pharma
Companies in the same business, of comparable size and area, outside its group.
- AONA Retail sale of pharmaceutical products Roeselare · balance sheet 290,456 €
- Pharmacie Ambiorix Retail sale of pharmaceutical products Brussels · balance sheet 290,535 €
- Theunissen-DE Neve Retail sale of pharmaceutical products Aalst · balance sheet 291,003 €
- LES Iles D'OR Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet 291,796 €
- Askela Retail sale of pharmaceutical products Chièvres · balance sheet 293,294 €
- Medipharm Anderlecht Retail sale of pharmaceutical products Evere · balance sheet 285,622 €
- Aksa Pharma Retail sale of pharmaceutical products Brussels · balance sheet 293,776 €
- Leveugle Retail sale of pharmaceutical products Deinze · balance sheet 297,608 €
Frequently asked questions about ACE Pharma
What is the revenue of ACE Pharma?
ACE Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ACE Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0436322331 for ACE Pharma, if the company is VAT-registered. Its company number (CBE) is 0436.322.331.
Where is the registered office of ACE Pharma?
According to the CBE register, the registered office of ACE Pharma is in 4347 Fexhe-le-Haut-Clocher.
What is the equity of ACE Pharma?
At the close of the 2025 financial year, the equity of ACE Pharma amounts to 221,792 €, a solvency of 76.6% of total assets.
How many people work at ACE Pharma?
0.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ACE Pharma?
The register lists 4 active mandates at ACE Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ACE Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →